2021 Revenues ($USD) : $18,973,220,000
2021 Revenues (foreign currencies) : €16,079,000,000
2021 R&D spend : $2,434,340,000
2021 Number of Employees : 42,592
Fiscal Year End : 12/31/2021
Leader : CEO Belén Garijo

The Darmstadt, Germany—based company achieved record growth in 2021, increasing sales for the overall group by 12.3% to €19.7 billion over the prior year. Also in 2021, the company elevated its status as a biopharmaceutical contract development and manufacturing organization (CDMO) with the acquisition of Exelead. It also acquired Chord Therapeutics, a biotech company focused on rare inflammatory disorders of the nervous system. —BB